Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in ES-SCLC
NCT05001412Phase 1Unknown
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of camrelizumab and Rivoceranib in small cell lung cancer (SCLC) (2 cohorts). Primary endpoint: Dose-limiting toxicities. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05001412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001412.